Eli Lilly antibody trial paused over safety concerns

Eli Lilly antibody trial paused over safety concerns

The late-stage study is looking at whether Lilly’s antibody, known as bamlanivimab, could help hospital patients. The treatment is a monoclonal antibody that mimics the antibodies the body makes naturally. It is similar to the Regeneron antibody cocktail that President Donald Trump recently received after he was diagnosed with Covid-19.

background: Last week, Lilly asked the FDA to issue an emergency clearance that would allow the antibody treatment to be used in high-risk patients recently diagnosed with mild to moderate Covid-19.

This application is largely based on preliminary data from a Phase II study published in mid-September, which found that patients who received a dose of the antibody were less likely to be hospitalized or to visit the emergency room.

What’s next: The data and safety oversight body overseeing the study will try to better understand what caused the safety concerns and whether or not to restart the study.


Please enter your comment!
Please enter your name here